Dyadic Announces Sale of Equity Interest in Alphazyme
19 janv. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Eascra Biotech Selected as Finalist for 2023 SXSW Pitch
18 janv. 2023 10h14 HE
|
Eascra Biotech
BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Eascra Biotech, a new start-up building the next generation of therapeutic nanotechnologies, was selected as a finalist in the “Innovative World...
Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
16 janv. 2023 07h00 HE
|
Avectas
DUBLIN, Ireland and CAMBRIDGE, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week,...
Global Messenger RNA (mRNA) Vaccines & Therapeutics Market Research Report 2022 Featuring Pfizer, GSK, Daiichi Sankyo, Intellia Therapeutics, Moderna, CureVac, Arcturus Therapeutics, & BioNTech
05 janv. 2023 04h03 HE
|
Research and Markets
Dublin, Jan. 05, 2023 (GLOBE NEWSWIRE) -- The "Messenger RNA (mRNA) Vaccines & Therapeutics Market, Size, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity...
Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference
04 janv. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
14 déc. 2022 08h30 HE
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
Pfizer und BioNTech geben frühe positive Daten aus klinischer Studie mit an Omikron BA.4/BA.5 angepasstem bivalenten Auffrischungsimpfstoff bei Personen ab 18 Jahren bekannt
13 oct. 2022 06h45 HE
|
BioNTech SE
Seren von Probandinnen und Probanden, die sieben Tage nach Verabreichung einer 30-µg-Auffrischungsimpfung mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff entnommen wurden,...
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
13 oct. 2022 06h45 HE
|
BioNTech SE
Sera collected from participants 7 days after administration of a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine showed a substantial increase in the Omicron BA.4/BA.5...
BioNTech Establishes Asia-Pacific Clinical Scale mRNA Manufacturing & Regional Research Centre
07 oct. 2022 09h00 HE
|
mRNA Victoria
MELBOURNE, Australia, Oct. 07, 2022 (GLOBE NEWSWIRE) -- mRNA Victoria announces that the developers of the Pfizer/BioNTech COVID-19 mRNA vaccine will also establish an Asia-Pacific mRNA clinical...
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
04 oct. 2022 08h45 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...